Comparison
CJC-1295 vs. Exenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
no data
141758-74-9
Molecular weight
3647.3 g/mol
4186.6 g/mol
Half-life
144 h
2.4 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
3
2